The incidence of pulmonary embolism during deep vein thrombosis

Phlebology

Volumn 28, Issue 1_suppl, 2013, Pages 29-33

  Nielsen, J D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

deep vein thrombosis; epidemiology; pulmonary embolism; risk factors; venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

BLOOD CLOTTING DISORDER; DEEP VEIN THROMBOSIS; HUMAN; INCIDENCE; LUNG EMBOLISM; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; PROGNOSIS; RISK ASSESSMENT; VEIN THROMBOSIS;

HUMANS; INCIDENCE; PROGNOSIS; PULMONARY EMBOLISM; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84883202943     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1177/0268355513477009     Document Type: Review

References (20)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 58: 585–93
2. Anderson FA, Jr, Wheeler HB, Goldberg RJ. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933–8
3. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657–60
4. Næss IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692–9
5. Falck-Ytter Y, Francis CW, Johanson NA. American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e278S–325S
6. Ageno W, Spyropoulos AC, Turpie AG. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thromb Haemost 2012; 107: 1027–34
7. Cohen AT, Tapson VF, Bergmann JF., for the ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387–94
8. Chopard P, Dörffler-Melly J, Hess U. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med 2005; 257: 352–7
9. Dahan R, Houlbert D, Caulin C. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 159–64
10. Samama MM, Cohen AT, Darmon JY. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793–800
11. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–9
12. Mahé I, Bergmann JF, d'Azémar P, Vaissie JJ, Caulin C. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. Eur J Clin Pharmacol 2005; 61: 347–51
13. Lederle FA, Sacks JM, Fiore L. The prophylaxis of medical patients for thromboembolism pilot study. Am J Med 2006; 119: 54–9
14. de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol 2000; 110: 125–9
15. Margaglione M, Brancaccio V, De Lucia D. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 2000; 118: 1405–11
16. Cushman M, Tsai AW, White RH. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19–25
17. Sorensen HT, Horvath-Puho E, Lash TL. Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation 2011; 124: 1435–41
18. Prandoni P, Pesavento R, Sorensen HT. Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey. Eur J Intern Med 2009; 20: 470–3
19. Cohen AT, Agnelli G, Anderson FA. VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756–64
20. Baglin T, Douketis J, Tosetto A. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010; 8: 2436–42